U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Gastric Adenocarcinoma

MedGen UID:
1712797
•Concept ID:
C5238242
•
Neoplastic Process

Definition

Gastric adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Gastric Adenocarcinoma

Professional guidelines

PubMed

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Advances in the treatment of gastric cancer.
Ilson DH
Curr Opin Gastroenterol 2018 Nov;34(6):465-468. doi: 10.1097/MOG.0000000000000475. PMID: 30303856
Advances in the treatment of gastric cancer.
Ilson DH
Curr Opin Gastroenterol 2017 Nov;33(6):473-476. doi: 10.1097/MOG.0000000000000395. PMID: 28877045

Recent clinical studies

Etiology

Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS
Med Clin North Am 2023 May;107(3):491-504. Epub 2023 Feb 20 doi: 10.1016/j.mcna.2023.01.002. PMID: 37001949
Liver resection after Transjugular Portosystemic Stent Shunt (TIPSS).
Sliwinski S, Trojan J, Mader C, Vogl T, Bechstein W
Z Gastroenterol 2023 Apr;61(4):390-393. Epub 2022 Jun 13 doi: 10.1055/a-1791-2192. PMID: 35697061
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H
J Clin Oncol 2016 May 1;34(13):1448-54. Epub 2016 Feb 16 doi: 10.1200/JCO.2015.63.5995. PMID: 26884585

Diagnosis

Refractory Diarrhea and Gastric Adenocarcinoma, Just a Coincidence?
Lu SY, Zhang H, Chen Y
Gastroenterology 2024 Mar;166(3):e1-e5. Epub 2023 Oct 6 doi: 10.1053/j.gastro.2023.09.044. PMID: 37806458
Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS
Med Clin North Am 2023 May;107(3):491-504. Epub 2023 Feb 20 doi: 10.1016/j.mcna.2023.01.002. PMID: 37001949
Refractory Chylothorax and Lymphedema Caused by Advanced Gastric Cancer.
Nagano N, Suzuki M, Tamura K, Kobayashi S, Kojima Y, Naka G, Iikura M, Izumi S, Takeda Y, Sugiyama H
Intern Med 2019 Nov 1;58(21):3143-3148. Epub 2019 Jul 10 doi: 10.2169/internalmedicine.2351-18. PMID: 31292374Free PMC Article
The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective.
Massironi S, Zilli A, Elvevi A, Invernizzi P
Autoimmun Rev 2019 Mar;18(3):215-222. Epub 2019 Jan 11 doi: 10.1016/j.autrev.2018.08.011. PMID: 30639639
Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
Pasricha G, Padhi P, Daboul N, Monga DK
Clin Ther 2017 Nov;39(11):2146-2157. doi: 10.1016/j.clinthera.2017.10.010. PMID: 29173655

Therapy

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Camrelizumab: First Global Approval.
Markham A, Keam SJ
Drugs 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0. PMID: 31313098
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M
Ann Oncol 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199. PMID: 31240302Free PMC Article
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Prognosis

Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS
Med Clin North Am 2023 May;107(3):491-504. Epub 2023 Feb 20 doi: 10.1016/j.mcna.2023.01.002. PMID: 37001949
The heterogeneity of cancer-associated fibroblast subpopulations: Their origins, biomarkers, and roles in the tumor microenvironment.
Yamamoto Y, Kasashima H, Fukui Y, Tsujio G, Yashiro M, Maeda K
Cancer Sci 2023 Jan;114(1):16-24. Epub 2022 Oct 19 doi: 10.1111/cas.15609. PMID: 36197901Free PMC Article
Liver resection after Transjugular Portosystemic Stent Shunt (TIPSS).
Sliwinski S, Trojan J, Mader C, Vogl T, Bechstein W
Z Gastroenterol 2023 Apr;61(4):390-393. Epub 2022 Jun 13 doi: 10.1055/a-1791-2192. PMID: 35697061
Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature.
Takada J, Araki H, Ozawa N, Sugiyama T, Kubota M, Ibuka T, Shimizu M
J Gastrointest Cancer 2019 Sep;50(3):556-559. doi: 10.1007/s12029-017-0043-6. PMID: 29250745
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Clinical prediction guides

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS
Med Clin North Am 2023 May;107(3):491-504. Epub 2023 Feb 20 doi: 10.1016/j.mcna.2023.01.002. PMID: 37001949
The treatment landscape for gastroesophageal adenocarcinomas.
Sonbol MB, Pathak S, Bekaii-Saab T
Clin Adv Hematol Oncol 2022 Mar;20(3):169-177. PMID: 36607347
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Recent systematic reviews

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA, Rha SY, Ohtsu A, Liepa AM, Knoderer H, Chatterjee A, Van Cutsem E
Oncologist 2021 Oct;26(10):e1704-e1729. Epub 2021 Sep 3 doi: 10.1002/onco.13907. PMID: 34288262Free PMC Article
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A, Park R, Sun W
J Hematol Oncol 2021 Jan 12;14(1):13. doi: 10.1186/s13045-021-01034-0. PMID: 33436042Free PMC Article
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T
Cochrane Database Syst Rev 2020 Nov 19;11(11):CD012078. doi: 10.1002/14651858.CD012078.pub2. PMID: 33210731Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...